文献速递淋巴瘤

SRC家族酪氨酸激酶HCK被鉴定为套细胞淋巴瘤的治疗靶点

Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.
PubMed 文献 · Leukemia · 2020-06-26

套细胞淋巴瘤(MCL)耐药仍是关键问题。研究发现SRC家族酪氨酸激酶造血细胞激酶(HCK)在MCL中异常表达,高表达与预后不良相关;HCK受TLR衔接蛋白MYD88调控,沉默HCK导致细胞周期阻滞和凋亡,并影响整合素介导的黏附。

要点

  • HCK在MCL中异常表达,高表达与MCL患者预后不良相关。
  • HCK表达受TLR衔接蛋白MYD88调控,TLR激动剂可增强MCL细胞系和原代MCL中HCK表达。
  • 沉默HCK导致细胞周期阻滞和凋亡,并控制整合素介导的MCL细胞黏附。

核心结论

  • TLR/MYD88调控的HCK异常表达在MCL增殖、生存及恶性细胞滞留于淋巴器官微环境中起关键作用,从而促进淋巴瘤发生。
  • 这些新见解为MCL中靶向HCK治疗提供了有力依据。

研究设计与样本

  • 研究采用MCL细胞系和原代MCL样本,分析HCK表达、调控及其功能。

主要发现

  • HCK在MCL中异常表达,高表达与MCL患者预后不良相关。
  • HCK表达受TLR衔接蛋白MYD88调控,TLR激动剂可增强MCL细胞系和原代MCL中HCK表达。
  • 高HCK表达的原代MCL富集TLR信号通路基因集。
  • 沉默HCK表达导致细胞周期阻滞和凋亡。
  • HCK控制整合素介导的MCL细胞与细胞外基质和基质细胞的黏附。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin lymphoma subtype arising from naïve B cells. Although novel therapeutics have improved patient prognosis, drug resistance remains a key problem. Here, we show that the SRC-family tyrosine kinase hematopoietic cell kinase (HCK), which is primarily expressed in the hematopoietic lineage but not in mature B cells, is aberrantly expressed in MCL, and that high expression of HCK is associated with inferior prognosis of MCL patients. HCK expression is controlled by the toll-like receptor (TLR) adaptor protein MYD88 and can be enhanced by TLR agonists in MCL cell lines and primary MCL. In line with this, primary MCL with high HCK expression are enriched for a TLR-signaling pathway gene set. Silencing of HCK expression results in cell cycle arrest and apoptosis. Furthermore, HCK controls integrin-mediated adhesion of MCL cells to extracellular matrix and stromal cells. Taken together, our data indicate that TLR/MYD88-controlled aberrant expression of HCK plays a critical role in MCL proliferation and survival as well as in retention of the malignant cells in the growth- and survival-supporting lymphoid organ microenvironment, thereby contributing to lymphomagenesis. These novel insights provide a strong rationale for therapeutic targeting of HCK in MCL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Lantermans HC, Minderman M, Kuil A, et al. Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma. Leukemia. 2020. PMID: 32591642. doi:10.1038/s41375-020-0934-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。